anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Generally, the present invention relates to the field of antibodies. In particular, it relates to multispecific antibodies, e.g. bispecific antibodies, which are modified such that the desired chain pairing takes place and/or can be selected for. Specifically, this is achieved by using different dimerization domains for light chain pairing. The invention further relates to nucleic acids encoding for these antibodies, expression vectors comprising these nucleic acids, cells expressing them, and further to pharmaceutical compositions comprising the antibodies. The invention also relates to methods of isolating the antibodies.
This is an open-label, randomised, single dose, 3-way crossover study to characterise and compare the PK, safety and tolerability of RDC5 in 15 healthy male volunteers. Eligible subjects will undergo 3 Treatment Periods, each separated by a washout period at least 14 days. Subjects will receive a single dose of RDC5 during each of the three Treatment Periods in line with their randomized treatment sequence. A total of 4 dose levels will be evaluated within the study, though each subject will only receive 3 doses. A Data Review Team (DRT) will review the pharmacokinetic (PK) data from Treatment Periods 1 and 2 and select the doses to be evaluated in Treatment Periods 2 and 3. Subjects will return for a follow visit 21 days after the last dose of RDC5.
As the conversion rate of preclinical studies for cancer treatment is low, user-friendly models that mimic the pathological microenvironment and drug intake with high throughput are scarce. Animal models are key, but an alternative to reduce their use would be valuable. Vascularized tumor-on-chip models combine great versatility with scalable throughput and are easy to use. Several strategies to integrate both tumor and vascular compartments have been developed, but few have been used to assess drug delivery. Permeability, intra/extravasation, and free drug circulation are often evaluated, but imperfectly recapitulate the processes at stake. Indeed, tumor targeting and chemoresistance bypass must be investigated to design promising cancer therapeutics. In vitro models that would help the development of drug delivery systems (DDS) are thus needed. They would allow selecting good candidates before animal studies based on rational criteria such as drug accumulation, diffusion in the tumor, and potency, as well as absence of side damage. In this review, we focus on vascularized tumor models. First, we detail their fabrication, and especially the materials, cell types, and coculture used. Then, the different strategies of vascularization are described along with their classical applications in intra/extravasation or free drug assessment. Finally, current trends in DDS for cancer are discussed with an overview of the current efforts in the domain.
Interventional Arm 3 - 15 patients allocated to this group will undergo bilateral sympathectomy, which will be performed using video assisted thoracoscopy using the Ethicon Ultracision device. The denervation consists of lower 1/3 stellate ganglion and T3- T4 thoracic interspinal space videothoracoscopic cutting, isolating the whole sympathetic chain between these two points using ultracision device on the nerve branches. The cephalic portion of the stellate ganglion will be preserved to avoid Horner's syndrome and the electrocautery use will also be avoided for the same reason. Hemodynamic and echocardiographic behaviors will be continuously monitored during these surgical maneuvers.
Patients assigned to this Arm received concurrent chemoradiotherapy. The prescribed dose of radiotherapy is generally 50-60 Gy/25-28fr. The concomitant chemotherapy is docetaxel 20 mg/m2 on day 1, cisplatin 25 mg/m2 on day 1, repeated weekly during radiation.
The patient should be instructed to:

  1. Use Ciclopirox Shampoo as directed by the physician. Avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water. Ciclopirox Shampoo is for external use on the scalp only. Do not swallow.
  2. Use the medication for seborrheic dermatitis for the full treatment time even though symptoms may have improved. Notify the physician if there is no improvement after 4 weeks.
  3. Inform the physician if the area of application shows signs of increased irritation (redness, itching, burning, blistering, swelling, or oozing) indicative of possible allergic reaction.
  4. Not use the medication for any disorder other than that for which it is prescribed.
<P>PROBLEM TO BE SOLVED: To provide a nutrient composition for diabetes or blood sugar control, effective for the blood sugar control and complication prevention of a diabetes patient, enabling sufficient nutritional management, and having good flavor.  <P>SOLUTION: The nutrient composition for the diabetes or the blood sugar control contains glucides, proteins, lipids, dietary fiber, vitamins and minerals as nutrient components. The composition further contains catechins originated from tea, and L-arabinose and/or an extract of leaves of mulberry. The content of vitamin C per 100 kcal is 30-150 mg, and the content of vitamin E per 100 kcal is 3-10 mg. The ratio by weight of the catechins originated from the tea to the L-arabinose and/or the extract of the leaves of the mulberry is (1:2) to (1:5). The content of the dietary fiber is preferably 5-10 wt.% based on the whole solid components.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The cold spray group consists of patients with ankle fractures who receive cold therapy using Perskindol cold spray containing Levomenthol. The spray is applied to the injured ankle 5-6 times, followed by a 10-minute break. This process is repeated every 2 hours for a total of 6 times (from 8:00 AM to 6:00 PM).
This group will include 160 women with unexplained recurrent implantation failure undergoing a trial of IVF/ICSI. This group will receive intravenous infusion of placebo, once between days 4 and 9 of the ovarian stimulation, and again within 7 days of a positive pregnancy test.
Participants will be prescribed 1-2 ferrous sulfate 325mg tablets by mouth (based on severity of anemia) until delivery. For standardization, the dosage is as follows based on severity: one ferrous sulfate tablet for women with baseline hemoglobin 9-11, and two ferrous sulfate tablets for hemoglobin \< 9.
In this research study, adult participants who have sustained a below-the-knee traumatic injury greater than two years ago and are still experiencing deficits including weakness and/or immobility will be assigned to one of two brace sequences (AB or BA). Participants will be randomized to a particular sequence, with an equal chance of getting either order. Participants will be evaluated under 4 conditions: no device, standard of care, and 2 carbon fiber custom dynamic orthoses (CDO), the Reaktiv device from FabTech Systems and the PhatBrace by Bio-Mechanical Composites Inc. Participants will be tested with no device and standard of care at baseline, after 3 months of accommodation to the Reaktiv, and 3 months of accommodation to the PhatBrace. A series of study measures will be performed. The physical performance measures will incorporate tests of agility, balance, speed and lower limb power. Questionnaires will be used to evaluate participant's perceived comfort and smoothness, pain, preference, and semi-structured interviews will be used to fully capture the perspective of the participant. A motion capture system will be used to evaluate walking mechanics, allowing comparisons between conditions. Lower limb forces and body motion will be assessed using computerized motion capture and force plates in the floor, as individuals walk over-ground. Small reflective markers placed on the participant's skin and force measuring plates in the floor will be used. The investigators will also complete mechanical testing of the devices and collect demographic and descriptive data.
Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the Central Nervous System (CNS). There are many forms of MS; althoughthe majority are Relapsing Remitting (RRMS) representing approximately 80% of the cases. The disease appears to be more inflammatory in RRMS as manisfested by an increase inGadolinium enhancement on MRI and an increase in inflammatory bioassay markers.

Zocor is in a class of drugs (statins) that are used to lower cholesterol. Statins also have an anti-inflammatory effect on the CNS. Zocor has been shown in a small clinical trial to reduce the number of new MRI-detected brain lesions over a six month treatment period in patients with RRMS. This study is to evaluate the safety of combining Avonex with Zocor for a a period of fourteen months in patients with RRMS and to evaluate the effect of treatment on new or enlarging lesions as measured by MRI.
PURPOSE:The titled food and drink, prepared by incorporating a powder or an extracted substance from Ganoderma lucidum Karst. in a coffee drink or powder, and having reduced toxic action of the coffee. CONSTITUTION:A food and drink, obtained by incorporating a powder or extracted substance from Ganoderma lucidum Karst. in an amount of 50-500mg/ day expressed in terms of water-soluble components of the Ganoderma lucidum Karst., and having reduced toxic action of the coffee components. The powder of extracted substance of the Ganoderma lucidum Karst. resembles the coffee in the sensation except a part of the flavor. The color is brown, and the taste is bitter. The flavor is of a vegetable smell, and the unique mushroom smell and bitterness are absorbed and softened by the flavor and the bitterness of the coffee. Thus, the components of the Ganoderma lucidum Karst. can be drunk and eaten without any unwillingness.
Each subject will be provided with a wearable device (smartwatch EmbracePlus manufactured by Empatica), to be worn every day outside of work hours for a total of 6 weeks. After the 6 weeks of data collection the participant will be asked to fill an online questionnaire related to the system usability (max 20 min).
PURPOSE:To obtain a hair tonic cosmetic capable of activating hair matrix cells and providing excellent hair growing, hair tonic, alopecic preventive and antidandruff effects by blending gamma-amino-beta-hydroxtbutyric acid with diisopropylamine dichloroacetate. CONSTITUTION:A hair tonic cosmetic containing at least one selected from compounds expressed by formula I and salts thereof and a compound expressed by formula II at 1:(0.1-1) weight ratio. The respective amounts of both are 0.05-2.0wt.% based on the total amount of the cosmetic. The compounds expressed by formula I are capable of activating hair matrix cells of the scalp, normalizing the scalp metabolic function, enhancing antidandruff effects and especially assuming remarkable effects by application thereof to male alopecia. Since the compound expressed by formula II has blood circulation promoting action, the aforementioned compound is capable of activating metabolism of hair roots and exhibiting promoting action on growth of the hair roots. Synergistic effects are obtained by using both in combination.
BACKGROUND: Chronic disease risk factors are increasing amongst adolescents, globally. Digital health prevention programs, which provide education and information to reduce chronic disease risk factors need to be equitable and accessible for all. For their success, multiple highly engaged stakeholders should be involved in development and implementation. This study aimed to evaluate stakeholders' support for, and perspectives on potential public health impact of digital health prevention programs for adolescents and potential pathways for future implementation.
METHODS: Qualitative semi-structured online interviews with stakeholders. Stakeholder mapping identified key individuals, groups and organizations across Australia that may influence the implementation of digital health prevention programs for adolescents. Recorded and transcribed interviews were analyzed within the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) Framework, using deductive content analysis.
FINDINGS: Nineteen interviews were conducted in 2023 with stakeholders from government, health, non-government organizations, youth services, education, community settings and others. Four overarching themes were identified: (i) existing digital health initiatives are not fit for purpose; (ii) the co-creation of digital health prevention programs is critical for successful implementation; (iii) digital health prevention programs must address equity and the unique challenges raised by technology and; (iv) system level factors must be addressed.
INTERPRETATION: Stakeholders broadly supported digital health prevention programs, yet raised unique insights to ensure that future programs create public health impact by improving chronic disease risk factors among adolescents. These insights can be applied in future development of digital health prevention programs for adolescents to strengthen widespread implementation.
FIELD: medicine, hemorheology, phytotherapy. SUBSTANCE: invention proposes an agent and a method of its preparing. Method involves the use of a dry extract from Leuzea carthamoides roots and rhizomes as a hemorheological agent obtained by extraction with 25-40% ethyl alcohol in the ratio raw : extractant = 1: 1 at temperature 18-20 C for 10-12 days. Invention can be used in treatment of cardiovascular, endocrine and other diseases accompanying with syndrome of enhanced blood viscosity. EFFECT: expanded arsenal of hemorheological agents of natural origin, absence of toxicity. 2 cl, 1 tbl
Extrapyramidal hyperkinetic movement disorders comprise a broad range of phenotypic phenomena, including chorea, dystonia, and tics. Treatment is generally challenging and individualized, given the overlapping phenomenology, limited evidence regarding efficacy, and concerns regarding the tolerability and safety of most treatments. Over the past decade, the treatment has become even more intricate due to advancements in the field of deep brain stimulation as well as optimized dopamine- depleting agents. Here, we review the current evidence for treatment modalities of extrapyramidal hyperkinetic movement disorders and provide a comprehensive and practical overview to aid the choice of therapy. Mechanism of action and practical intricacies of each treatment modality are discussed, focusing on dosing and adverse effect management. Finally, future therapeutic developments are also discussed.
High pain intensity is a common symptom experienced by patients with serious advanced illness. However, pain management for patients in home hospice is less than optimal. Impediments to improving pain intensity are poor adherence to pain management regimen due in part to caregiver lack of knowledge (a barrier to reporting pain and using analgesics) and lack of self-efficacy (confidence) in administering analgesics. Digital applications may facilitate pain management by: (1) delivering education to increase knowledge and self-efficacy, (2) expediting pain reporting to nurses, and (3) improving adherence to pain management. e-PainSupport is a self-administered, digital pain management application developed in collaboration with hospice nurses and caregivers. It is directly linked to a patient's medical record and enhanced by an evidence-based educational module. It has three elements: (a) Educational Module, (b) Patient Pain Record, and (c) Pain Summary for Nurses. The purpose of this study is to test the effects of e-PainSupport on home hospice patient pain intensity when used by patients, caregivers and nurses. Participants (132 triads of patient, caregiver, and the hospice nurse assigned to the patient will be recruited from one large Midwest hospice agency. Patient and caregiver outcomes will be assessed at baseline and 2 weeks post baseline. Data will be analyzed with multi-level modeling. Post-intervention semi-structured interviews will be conducted with nurses who provided care to patients in the e-PainSupport condition. Qualitative content analysis will be used to identify themes related to perceived practice changes after using e-PainSupport. e-PainSupport has potential as a useful tool to advance home hospice care by enhancing the quality of caregiver pain management, facilitating nurse-patient communication, and improving management of patient pain intensity.
PURPOSE: To make it possible to obtain thin films of sample cosmetics by discharging a coating liquid in a dispersion form formed by incorporating cosmetic powder and thickener into a dispersion to a thin film form by an airless nozzle of a flat pattern under a low liquid pressure. CONSTITUTION: The coating liquid in the dispersion form is prepd. by incorporating the cosmetic powder and cellulose ester of a nonionic system as the thickener into the dispersion consisting of a mixture composed of ethanol and liquid paraffin. When the coating liquid is discharged under the low liquid pressure by the airless nozzle 11 of the flat pattern, the discharged coating liquid forms a thin liquid film 10 without fogging. Then, the thin liquid film 10 is moved relative to backing paper 2, by which the thin coating film is formed in the prescribed position of the backing paper 2 without masking the backing paper 2. As a result, the thin layer of the sample cosmetics is formed.
A sweetener additive for use with consumable products, such as foods and beverages, to sweeten the consumable product and provide health benefits to a consumer who consumes a consumable product. The sweetener additive has a sweetener base and one or more of selected flavonoids. The sweetener base has one or more sweeteners commonly utilized to sweeten consumable products. The flavonoids may be extracted from plants chosen from the genus Hovenia, such as the Japanese raisin tree. The selected flavonoids provide various health benefits, including stimulating naturally occurring enzymes in the consumer's body. One or more aldehyde reducing enzymes, one or more glucose reducing enzymes and/or one or more alcohol reducing enzymes may be added to the sweetener additive to supplement naturally occurring enzymes in the consumer's body to reduce the deleterious effects of aldehydes, glucose and/or alcohol on the consumer. The flavonoids will also stimulate the added enzymes.
PURPOSE: To obtain an isatoic acid anhydride derivative and its salt useful for medicines, especially as an inhibitor of neutrophilic esterases. CONSTITUTION: This compound is expressed by formula I (R1 is H or a lower alkyl group; X is CO, SO2 , etc.; R2 is a lower alkyl group, a lower alkoxy group, etc.), e.g. 7-(benzoylamino)isatoic acid anhydride. The compound of formula I is obtained by carrying out the cyclizing, reducing and condensing reactions of a compound of formula II (R1 is H or methyl), e.g. 4-nitroanthranilic acid or 4-nitro-6-methylanthranilic acid as a starting compound. The cyclizing reaction is preferably carried out by reacting, e.g. the compound of formula II with triphosgene in an organic solvent such as tetrahydrofuran at ambient temperature and the reducing reaction is preferably conducted by catalytically reducing the resultant cyclized compound of formula II in the presence of palladium carbon or a palladium hydroxide catalyst in an organic solvent such as methanol in a hydrogen atmosphere.  Furthermore, the condensing reaction is preferably carried out by reacting the reduction product with an acid halide in the presence of a base such as triethylamine in an organic solvent such as tetrahydrofuran at ambient temperature.
The invention provides a drug combination for analgesia, anesthesia or drug rehabilitation. The drug combination is composed of a tetrodotoxin injection and an opioid medical injection which are packaged separately. The tetrodotoxin injection is composed of tetrodotoxin containing a buffer agent and a high penetrating agent for opening of the blood-brain barrier (BBB) or a BBB carrier. The opioid medical injection is a commercially available injection containing an opioid receptor stimulant. In the drug combination for analgesia, anesthesia or drug rehabilitation, the BBB-opening high penetrating agent or the BBB carrier can raise BBB permeability and bioavailability of tetrodotoxin and the opioid medicine, and tetrodotoxin has a synergistic effect of de-addiction and synergism. Through cooperation of the three drugs, the drug therapeutic effect can be enhanced, duration of drug effect is prolonged, dosage of the opioid medicine is reduced, and tolerance and dependency of the opioid medicine are decreased or eliminated.
PROBLEM TO BE SOLVED: To obtain a skin-conditioning cosmetic composition which shows an excellent skin-conditioning effect and is effective on aging change and useful as a cosmetic or the like by including an elastase activity inhibitor and a collagen synthesis promotor. SOLUTION: This cosmetic composition is obtained by mixing (A) an elastase activity inhibitor, suitably an essence of Engelhardtia chrysolepis H and/or a soybean protein, with (B) a collagen synthesis promotor, suitably one or more than two kinds selected from a suifated arginic acid, its physiologically permissible salt and an essence of malt. Further, it is favorable that the components A and B are contained, for example, in amounts of about 0.01-10 wt.% and about 0.01-10 wt.%, respectively, and a hydrocarbon, e.g. Vaseline or the like, an ester, e.g. jojoba oil or the like, glyceride, e.g. beef tallow or the like, a higher alcohol, e.g. cetyl alcohol or the like, or the like is additionally added.
DUSPs, a diverse group of protein phosphatases, play a pivotal role in orchestrating cellular growth and development through intricate signaling pathways. Notably, they actively participate in the MAPK pathway, which governs crucial aspects of plant physiology, including growth regulation, disease resistance, pest resistance, and stress response. DUSP is a key enzyme, and it is the enzyme that limits the rate of cell metabolism. At present, complete understanding of the DUSP gene family in cotton and its specific roles in resistance to Verticillium wilt (VW) remains elusive. To address this knowledge gap, we conducted a comprehensive identification and analysis of four key cotton species: Gossypium arboreum, Gossypium barbadense, Gossypium hirsutum, and Gossypium raimondii. The results revealed the identification of a total of 120 DUSP genes in the four cotton varieties, which were categorized into six subgroups and randomly distributed at both ends of 26 chromosomes, predominantly localized within the nucleus. Our analysis demonstrated that closely related DUSP genes exhibited similarities in terms of the conserved motif composition and gene structure. A promoter analysis performed on the GhDUSP gene promoter revealed the presence of several cis-acting elements, which are associated with abiotic and biotic stress responses, as well as hormone signaling. A tissue expression pattern analysis demonstrated significant variations in GhDUSP gene expression under different stress conditions, with roots exhibiting the highest levels, followed by stems and leaves. In terms of tissue-specific detection, petals, leaves, stems, stamens, and receptacles exhibited higher expression levels of the GhDUSP gene. The gene expression analysis results for GhDUSPs under stress suggest that DUSP genes may have a crucial role in the cotton response to stress in cotton. Through Virus-Induced Gene Silencing (VIGS) experiments, the silencing of the target gene significantly reduced the resistance efficiency of disease-resistant varieties against Verticillium wilt (VW). Consequently, we conclude that GH_A11G3500-mediated bispecific phosphorylated genes may serve as key regulators in the resistance of G. hirsutum to Verticillium wilt (VW). This study presents a comprehensive structure designed to provide an in-depth understanding of the potential biological functions of cotton, providing a strong foundation for further research into molecular breeding and resistance to plant pathogens.